Investors

Committed to growth and innovation

Vytrus Biotech is a biotechnology company that develops cosmetic active ingredients from plant stem cell technology at industrial scale.

The firm is located in Terrassa (Barcelona, Spain) and commercializes its products in more than 50 countries around the world through its network of international distributors.
ACCESS TO CORPORATE WEBSITE
Stay informed about our corporate news



    Investor profile


    Share information

    This section will provide the reader with further details in the coming weeks.

    ACCESS TO BME Growth WEBSITE

    Financial data

    Find and download Vytrus Biotech financial information

    Key documents

    Informe de auditoría de Vytrus 2023

    03/04/2024

    PDF

    Revisión limitada de auditoría Vytrus primer semestre 2023

    20/10/2023

    PDF

    Informe de auditoría de Vytrus 2022

    28/03/2023

    PDF

    Revisión limitada de auditoría Vytrus primer semestre 2022

    20/10/2022

    PDF

    Informe de auditoría de Vytrus 2021

    25/04/2022

    PDF

    Revisión limitada 2021

    31/08/2021

    PDF

    Informe de auditoría de Vytrus 2020

    10/05/2021

    PDF

    Informe de auditoría de Vytrus 2019

    11/05/2020

    PDF

    Press room

    Read latest news about Vytrus Biotech:

    11/04/2024

    Vytrus Biotech increases sales by 32% and EBITDA by 92% in the first quarter of 2024

    The cosmetic firm has released its unaudited results for the first quarter of 2024. The biotech company exceeds 4 million in sales year-on-year, with the United States and Europe being the markets where it grew the most.

    PDF

    28/02/2024

    Vytrus expects to triple its sales and reach 12 million euros in turnover by 2027.

    The biotechnology company has published its Strategic Plan for the period 2024-2027. As a result of the strategy that will set the company's course over the next 4 years, Vytrus Biotech expects to multiply its sales by 3 to 12 million euros and its EBITDA by 4 to 5 million euros in 2027.

    PDF